Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Senolytx logo — STX develops medicines targeting damaged cells to improve hu...

Senolytx

STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases.

Founded 2017 Spain Spain 2 employees Grant Total: $571.43K Biopharma, Biotechnology +3

General Information

Company Name Senolytx
Founded Year 2017
Location Spain Spain
Founders / Decision Makers
Team member
Employees 2
Industries Biopharma, Biotechnology, Medical Devices +2
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Senolytx. To contact Senolytx, visit senolytx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Senolytx compare?

A PDF of Senolytx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Senolytx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Senolytx

Senolytx is a biopharmaceutical startup founded in 2017 with a mission to develop medicines targeting damaged cells to advance therapies for aging-associated diseases. Its slogan, "STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases," captures the essence of its core focus. The company, located in Boston (US) and Barcelona (Spain), operates in the Biopharma, Biotechnology, Pharmaceutical, and Robotics industries. It recently received a €71.43K Grant investment on 01 August 2018 from the EASME - EU Executive Agency for SMEs. Senolytx's dedicated efforts are directed towards advancing its portfolio of therapies to clinical trials, aiming to ultimately improve the lives of patients and families affected by aging-associated diseases. Senolytx represents a promising player in the biopharmaceutical space, with its innovative approach and strategic presence in both the US and Spain, offering a significant advantage in accessing diverse markets and resources. As a potential investment opportunity, Senolytx's focus on addressing unmet medical needs and its progressive approach to tackling age-related diseases make it an attractive prospect for venture capitalists seeking to invest in impactful healthcare innovations.

Business keywords: pharmaceuticals, medicine development, clinical trials, aging-associated diseases, cell targeting therapy, Boston, Barcelona, therapeutics, innovation, biomedical technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant €71.43K 1
EASME - EU Executive Agency for SMEs
01 Aug 2018
Seed Round $500.00K -
07 Aug 2017

Senolytx Alternatives & Competitors

View All Alternatives
Senolytx vs
Spur Therapeutics
Spur Therapeutics United Kingdom

Toward the next generation of gene therapy.

Post-IPO Equity
122 employees
Biopharma, Biotechnology
Senolytx vs
Cavion
Cavion

Empowering therapies for cancer and neurologic diseases through pioneering ion channel inhibition

Series A
Biotechnology, Health Care
Senolytx vs
Athersys
Athersys United States

Committed to developing therapies to extend and enhance the quality of life.

Post-IPO Equity
37 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Senolytx

STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases.
Senolytx was founded in 2017.
Senolytx is headquartered in Spain.
Senolytx operates in Biopharma, Biotechnology, Medical Devices, Pharmaceutical and Robotics. Its work centres on pharmaceuticals, medicine development, clinical trials and aging-associated diseases.
Senolytx has approximately 2 employees.
Senolytx has completed 2 funding rounds, raising a total of $571.43K. The latest funding stage is Grant.
Top alternatives and competitors to Senolytx include Spur Therapeutics, Cavion, Athersys, Quanta Therapeutics, Arven Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Senolytx and Spur Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Senolytx, https://bouncewatch.com/company/senolytx, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes